RBC Capital analyst Daniel Busb reiterated an Outperform rating and $18.00 price target on Flexion Therapeutics (NASDAQ: FLXN) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE